Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma |
Gwak, Ho-Shin
(Registration Group)
Yee, Gi Taek (Registration Group) Park, Chul-Kee (Registration Group) Kim, Jin Wook (Registration Group) Hong, Yong-Kil (Registration Group) Kang, Seok-Gu (Registration Group) Kim, Jeong Hoon (Registration Group) Seol, Ho Jun (Registration Group) Jung, Tae-Young (Registration Group) Chang, Jong Hee (Registration Group) Yoo, Heon (Registration Group) Hwang, Jeong-Hyun (Registration Group) Kim, Se-Hyuk (Registration Group) Park, Bong Jin (Registration Group) Hwang, Sun-Chul (Registration Group) Kim, Min Su (Registration Group) Kim, Seon-Hwan (Registration Group) Kim, Eun-Young (Registration Group) Kim, Ealmaan (Registration Group) Kim, Hae Yu (Registration Group) Ko, Young-Cho (Registration Group) Yun, Hwan Jung (Registration Group) Youn, Ji Hye (Registration Group) Kim, Juyoung (Korean Society for Neuro-Oncology, Pharmaceutical Benefit Department, Health Insurance Review and Assessment Service) Lee, Byeongil (Korean Society for Neuro-Oncology, Pharmaceutical Benefit Department, Health Insurance Review and Assessment Service) Lee, Seung Hoon (Registration Group) |
1 | Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, et al. : Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma : a prospective GICNO study. J Clin Oncol 24 : 4746-4753, 2006 DOI ScienceOn |
2 | Brandes AA, Tosoni A, Vastola F, Pasetto LM, Coria B, Danieli D, et al. : Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer 101 : 2079-2085, 2004 DOI ScienceOn |
3 | Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al. : Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma : Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24 : 2707-2714, 2006 DOI ScienceOn |
4 | Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, et al. : Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12 : 2013-2021, 1994 DOI |
5 | Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. : Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma : Long-Term Results of RTOG 9402. J Clin Oncol 31 : 337-343, 2013 DOI |
6 | van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, et al. : Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors : the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21 : 2525-2528, 2003 DOI ScienceOn |
7 | Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. : IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 : 765-773, 2009 DOI ScienceOn |
8 | Yang SH, Kim MK, Lee TK, Lee KS, Jeun SS, Park CK, et al. : Temozolomide chemotherapy in patients with recurrent malignant gliomas. J Korean Med Sci 21 : 739-744, 2006 DOI ScienceOn |
9 | Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. : A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83 : 588-593, 2000 DOI ScienceOn |
10 | Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. : Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17 : 2762-2771, 1999 DOI |
11 | Reifenberger G, Louis DN : Oligodendroglioma : toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62 : 111-126, 2003 DOI |
12 | Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. : Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17 : 510-522, 2010 DOI ScienceOn |
13 | Peterson K, Paleologos N, Forsyth P, Macdonald DR, Cairncross JG : Salvage chemotherapy for oligodendroglioma. J Neurosurg 85 : 597-601, 1996 DOI ScienceOn |
14 | Pobereskin LH, Chadduck JB : Incidence of brain tumours in two English counties : a population based study. J Neurol Neurosurg Psychiatry 69 : 464-471, 2000 DOI |
15 | Soffietti R, Ruda R, Bradac GB, Schiffer D : PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43 : 1066-1073, 1998 DOI |
16 | Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T : Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas : a clinical efficacy trial. J Neurooncol 79 : 153-157, 2006 DOI |
17 | van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al. : Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma : long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31 : 344-350, 2013 DOI ScienceOn |
18 | van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, et al. : Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 51 : 1140-1145, 1998 DOI ScienceOn |
19 | van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al. : Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas : a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24 : 2715-2722, 2006 DOI ScienceOn |
20 | van den Bent MJ, Chinot O, Boogerd W, Bravo Marques J, Taphoorn MJ, Kros JM, et al. : Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy : EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14 : 599-602, 2003 DOI ScienceOn |
21 | Chamberlain MC, Glantz MJ : CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. J Neurooncol 89 : 231-238, 2008 DOI |
22 | Chamberlain MC, Johnston S : Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer 115 : 1734-1743, 2009 DOI ScienceOn |
23 | Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, et al. : Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19 : 2449-2455, 2001 DOI |
24 | Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, et al. : Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 83 : 53-60, 2007 DOI |
25 | Ducray F, del Rio MS, Carpentier C, Psimaras D, Idbaih A, Dehais C, et al. : Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. J Neurooncol 101 : 457-462, 2010 |
26 | Gan HK, Rosenthal MA, Dowling A, Kalnins R, Algar E, Wong N, et al. : A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors. Neuro Oncol 12 : 500-507, 2009 |
27 | Mikkelsen T, Doyle T, Anderson J, Margolis J, Paleologos N, Gutierrez J, et al. : Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J Neurooncol 92 : 57-63, 2009 DOI |
28 | Gaya A, Rees J, Greenstein A, Stebbing J : The use of temozolomide in recurrent malignant gliomas. Cancer Treat Rev 28 : 115-120, 2002 DOI ScienceOn |
29 | Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG : Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8 : 1277-1280, 1990 DOI |
30 | Macdonald DR, Gaspar LE, Cairncross JG : Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27 : 573-574, 1990 DOI ScienceOn |
31 | Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, et al. : Phase I trial of temozolomide (CCRG 81045 : M&B 39831 : NSC 362856). Br J Cancer 65 : 287-291, 1992 DOI ScienceOn |
32 | Balmaceda C, Peereboom D, Pannullo S, Cheung YK, Fisher PG, Alavi J, et al. : Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer 112 : 1139-1146, 2008 DOI ScienceOn |
33 | Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, et al. : Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12 : 259-266, 2001 DOI ScienceOn |
34 | Mohile NA, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, et al. : A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma : an interim analysis. J Neurooncol 89 : 187-193, 2008 DOI |
![]() |